Serotonin toxicity and cytochrome p450 poor metaboliser genotype patient case

Abstract
Serotonin toxicity commonly occurs in the context of serotonergic drug overdose or from interactions between multiple serotonergic agents. We describe a 29 year old woman with depression and anxiety who was commenced on regular fluoxetine 20mg/day for 7 weeks, followed by 40mg/day for 3 weeks. During the 10 week period she began to have increasing agitation and episodes of flushing, sweating and tremor. She presented to the emergency department with a similar acute episode. Following cessation of fluoxetine and treatment with cyproheptadine and diazepam, her symptoms improved and she was discharged the following day. Informed consent was obtained from the patient for genetic testing of her CYP enzymes. Restriction Fragment Length Polymorphism assay (PCR-RFLP) revealed a presence of homozygote rs3892097 and rs1065852 polymorphisms in CYP2D6 and heterozygote 2C19 rs4244285/rs4986893 polymorphisms, which are associated with poor metaboliser phenotype and presence of one copy of CYP1A2 rs35694136 and rs762551. This patient genotype is a very rare case of combined loss-of-function of CYP2D6 and CYP2C19 isoforms. In addition, heterozygote polymorphisms, which are associated with impaired activity of CYP1A2, possibly contribute to low activity of the cytochrome P450 drug metabolising pathway. The involved cytochrome P450 isoforms exhibit genetic polymorphisms that affect their catalytic activity.

Keywords: serotonin syndrome, genetic polymorphism, cytochrome p-450, cyp2d6, cyp2c19, cyp1a2

Abbreviations: ED, emergency department; GP, general practitioner; ST, serotonin toxicity; CYP, cytochrome P450; SSRI, selective serotonin reuptake inhibitor

Graphical abstract
Serotonin toxicity developed by patient with loss-of function Cytochrome P450 P450 genetic polymorphisms’ combination is described. Genotyping revealed CYP2D6, CYP2C19 and CYP1A2 non-functional polymorphisms previously associated with poor metaboliser phenotype.

Introduction

Case
A 28 year-old female patient was admitted to the emergency department (ED) for anxiety and agitation including increased sweating of palms and restless legs. She had been treated with antidepressants by her general practitioner (GP) for 2 years. Her medication was switched 2 months previously and three weeks prior to presentation to ED, her GP increased the fluoxetine dose from fluoxetine 20mg/day, to 40mg daily. On admission, the patient was confused, irritable, restless and agitated. Her physical examination was significant for tachycardia (122 beats/minute), hypertension (systolic BP 147 mmHg) and agitation. Neurologic examination was positive for hyperreflexia and clonus. She denied thoughts of self-harm, was compliant with medications, alert and orientated. Her background included smoking 10–15 cigarettes per day, and she had a family history of anxiety (both her mother and brother); she had no known allergies. Routine laboratory investigations were normal except for hypokalaemia (K). Serotonin toxicity was suspected and fluoxetine was ceased. Cyproheptadine 4mg and diazepam 5mg were administered to reduce agitation and serotonergic symptoms.

Doxepin (50mg daily) was recommended after 1 week medication-free time. Potassium replacement was given orally and the patient was discharged home on the following day. This case represents a clinically diagnosed serotonin toxicity occurring during normal prescribed doses of fluoxetine. Poor metaboliser status was suspected and a blood sample was collected for the genotyping analysis with the patient’s consent. In addition, the Liquid Chromatography QTOF MS blood test revealed fluoxetine in concentration off 0.34mg/L, however, norfluoxetine was not included in the MS test.

Serotonin toxicity
Serotonin toxicity (ST), or often referred to as serotonin syndrome, is a potentially lethal adverse effect due to serotonergic overactivity. Often under-recognized, serotonin toxicity is an important diagnosis to make as the prognosis is favourable if detected early and complications are managed appropriately.

ST involves several serotonin receptor sub-types. Potential mechanisms of serotonin toxicity include:

a. Increased serotonin synthesis or release
b. Reduced serotonin reuptake or metabolism
c. Direct serotonin receptor activation

Based on the Clinical Information Access Portal data, specific agents that may be implicated in ST include: amphetamines and their derivatives, analgesics, antidepressants/mood stabilisers, monoamine oxidase inhibitors SSRIs, serotonin-norepinephrine reuptake inhibitors, serotonin 2A receptor blockers, St. John’s Wort, trycyclic antidepressants, anti-emetics and anti-migraine drugs. Miscellaneous agents that may cause serotonin toxicity include cocaine, dextromethorphan, linezolid, l-tryptophan and 5-hydroxytryptophan.
In clinical practice, ST is diagnosed using the Hunter Serotonin Toxicity Criteria. ST has most commonly been reported when patients concomitantly receive two or more serotonergic agents, for example a combination of a monoamine oxidase inhibitor and a monoamine reuptake inhibitor. Reports suggest that ST can occur with single agent overdose and even with therapeutic dosing. Currently, no specific tests are available for the diagnosis of ST and blood serotonin levels do not correlate with clinical findings.

ST is a recognised adverse drug reaction to serotonergic psychotropics. As stated by Iqbal and co-authors, variations in drug response may be due to age, gender, morbidity, co-medication, food components, smoking and environmental factors. However, polymorphisms present in genes involved in drug metabolism, are responsible for most of the variations. Several pharmacogenetic factors were identified by studies involved ‘pharmacokinetic pathways candidate gene approach’ and CYP enzymes, dopamine and serotonin gene variants have been linked with treatment-associated side effects of psychotropic drugs. CYP 2D6, 2C19 and 2C9 are the most studied cytochrome P450 enzymes. Based on the CYP nomenclature website per-reviewed data, the most frequent variations in Phase 1 metabolism of drugs are consequences of gene polymorphisms or duplications. Authors contributed it to the fact that nearly 80% of all drugs in current practice, along with most psychotropics, are metabolised via these pathways. According to previously analysed data, patients with drug-induced akathisia have a higher prevalence of abnormal metaboliser genotypes. Serotonin pathway gene variants have also been linked to the development of adverse drug reactions, including the development of neurotoxicity.

Methods

Informed consent was obtained from the patient for genetic testing of her CYP enzymes. We have analysed variant alleles of CYP2D6*4/3892097, CYP2D6*5 (DEL), CYP2C19*2 rs4244285, CYP2C19*3 rs4986893, CYP2C9*2 rs1799853, CYP2C9*3 rs1057910, CYP1A2*1D rs35694136, CYP1A2*1F rs762551, CYP2D6*41 rs28371725, CYP3A4 rs2740574, CYP3A6*10(4*) rs1065852 that affect the function of cytochrome enzymes. DNA was extracted from blood using the manufacturer’s protocol for the QIAGEN EZ1 BioRobot system. The genotyping method involves specific restriction enzyme digestion of amplified PCR products (PCR-RFLP) and fragment analysis based on capillary electrophoresis Agilent Bioanayler methodology described in our previous publication.

Results

Restriction Fragment Length Polymorphism assay (PCR-RFLP) revealed a presence of homozygote rs3892097 and rs1065852 polymorphisms in CYP2D6 and heterozygote 2C19 rs4244285/ rs4986893 polymorphisms, which are associated with poor metaboliser phenotype and presence of one copy of CYP1A2 rs35694136 and rs762551.

Discussion

The constructive guidance for psychotropich drug prescription remains the subject of new developments in medicine. Nevertheless, the latest progress in science and biotechnology provides insights into drug pharmacokinetic and pharmacodynamic pathways. Drug metabolism can be analysed on the basis of genetic variations in metabolising enzymes and these variations can be tested in medical laboratories. Due to adverse drug reactions, which can sometimes even be life-threatening, prescription guidelines and recommendations are critical for drug safety in psychiatry.

Cytochrome P450

CYP is a group of oxidative/dealkylating enzymes, which are responsible for the primary metabolism of many drugs, accounting for about 75% of the total number of different metabolic reactions. CYP enzymes are localised in the microsomes of many tissues, including the intestines and liver, and participate in hydroxylation or dealkylation of many commonly prescribed psychotropics such as antidepressants and antipsychotics. In principle, the majority of psychotropic drugs are metabolised by the cytochrome P450 (CYP) family of enzymes. CYP-related metabolites of these drugs are highly chemically active molecules, so consequently they are likely to be associated with toxicity or unpredicted adverse reactions. Genes for most CYP isozymes are extremely polymorphic, that is, they frequently contain altered DNA, which can produce variants of the enzyme, and when this occurs, the activity of the enzyme is affected. The genetic polymorphism in CYP enzymes is a major factor in the individual variability of drug metabolism.

Identified SNPs

rs3892097 (CYP2D6*4) is the most common non-functional allele of CYP2D6 gene. It was demonstrated that homozygote genotype results in a non-functional protein formation. This non-functional allele was described in association with neuroleptic malignant syndrome, metoprolol pharmacokinetics/pharmacodynamics modulation, metoclopramide side effect, tamsulosin efficacy, colchicine efficacy, with environmental sensitivity-related illnesses, enhancing susceptibility to head and neck squamous cell carcinoma and chemotherapeutic response, increased incidence of systemic sclerosis, the risk of Parkinson’s disease and Poor Metaboliser phenotype for several drugs. Patients with the *4/*4 diplotype and depression may require a lower dose of citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine or sertraline as compared to patients with the *1/*1 genotype. Rs1065852 variant is described in association with poor metabolisers of debrisoquine amitriptyline, nortriptyline and fluvoxamine. Thermal instabilities and reduced intrinsic clearance by the protein encoded by the rs1065852 (T) allele were described. CYP2C19 rs4244285/rs4986893 combined effect on protein function create a decrease activity of cytochrome enzyme. It was demonstrated that patients with two no function CYP2C19 alleles (*2/*3) may have decreased metabolism of mephentoin, diazepam, esomeprazole. Patients with the CYP2C19 *2/*3 genotype infected with Helicobacter pylori may have an increased likelihood of eradication when treated with proton pump inhibitors. It was demonstrated that CYP1A2 rs35694136 and rs762551 have a significant impact on clozapine and theophylline serum concentration.

Fluoxetine

According to the MIMS Online (Medicine Information portal) data, fluoxetine is a selective serotonin reuptake inhibitor (SSRI) and is used for the treatment of major depressive disorder, obsessive compulsive disorder, bulimia nervosa and panic disorder. Fluoxetine is extensively metabolized in the liver by several cytochrome P450 enzymes with CYP2D6 being a major contributor. At the same
time, fluoxetine is an inhibitor of the CYP2D6 enzyme pathway and a potential drug-drug interaction substrate.\textsuperscript{13} Co-administration of fluoxetine with other drugs that are metabolised by CYP2D6 can convert a normal CYP2D6 metaboliser to a poor metaboliser. Fluoxetine and norfluoxetine are inhibitors of CYP2D6 mediated reactions and demonstrated inhibitory potency toward CYP2C19, CYP2C9, and CYP3A4 in \textit{in vitro} studies.\textsuperscript{6, 35} Several drugs metabolised by these enzymes, hence fluoxetine can influence metabolism and pharmacokinetics of coadministered drugs. Clinically relevant drug interactions have been reported with tricyclic antidepressants and neuroleptics through the interaction with isozyme CYP2D6.\textsuperscript{6} As recommended by the FDA label,\textsuperscript{6, 36} “therapy with medications that are predominantly metabolized by the CYP2D6 system and that have a relatively narrow therapeutic index should be initiated at the low end of the dose range if a patient is receiving fluoxetine concurrently or has taken it in the previous 5 weeks. Thus, his/her dosing requirements resemble those of poor metabolizers. If fluoxetine is added to the treatment regimen of a patient already receiving a drug metabolized by CYP2D6, the need for decreased dose of the original medication should be considered”. Fluoxetine’s metabolism involves the Cytochrome P450 system (Figure 1), and a combination of drugs which are also metabolised by CYPs may lead to drug interactions, even if fluoxetine has been discontinued for 4-5 weeks.\textsuperscript{53, 57-61} Fluoxetine is a racemic mixture of two enantiomers and its pharmacokinetics are complex. Norfluoxetine, an active metabolite of fluoxetine, is formed by demethylation.\textsuperscript{42} S-fluoxetine is more potent in the inhibition of serotonin reuptake than R-fluoxetine. However, the active metabolite S-norfluoxetine has about 20 times higher reuptake blocking potency than its R-enantiomer.\textsuperscript{62} S-fluoxetine, R-fluoxetine, S-norfluoxetine and R-norfluoxetine also have differential kinetics. The Fuller and co-authors demonstrated that that after several weeks of treatment, the plasma concentration of both S-enantiomers is about two times higher than its R-enantiomer.\textsuperscript{65}

**Figure 1** Pharmacokinetics of fluoxetine.\textsuperscript{46} Copyright to Pharm GKB. Image reproduced by permission of Pharm GKB and Stanford University, https://www.pharmgkb.org/pathway/PA161740017#PGG.

Fluoxetine is eliminated mostly through oxidative metabolism and conjugation\textsuperscript{42} and excreted in urine with less than 10% excreted unchanged or as fluoxetine glucuronide.\textsuperscript{64} Majority of the metabolic end products are unknown. As described by some authors, CYP2D6, CYP2C19, CYP2C9, CYP3A4, and CYP3A5 involved in the biotransformation of R- and S-fluoxetine to their N-desmethyl metabolites.\textsuperscript{65, 66} It was also demonstrated that CYP2C9 catalyzes R-fluoxetine demethylation and the formation of S-norfluoxetine is highly dependent on CYP2D6.\textsuperscript{65, 67} Their catalytic activities depend on genetic polymorphisms. Moreover, fluoxetine has demonstrated inhibitory potency toward CYP2C19, CYP2C9, and CYP3A4, consequently having the potential to alter metabolism and pharmacokinetics of coadministered drugs metabolised through the same pathway or its own metabolism.

**Conclusion**

Despite the data provided by some studies, serotonin toxicity phenotype versus genotype association still needs more evidence-based research data. In the described case, the phenotype of ST was likely a consequence of variation in Cytochrome P450 enzyme activity caused by genetic variations in CYP genes. Cytochrome P450 isoforms are a major determinant of the pharmacokinetic behaviour of psychotropic drugs. This case demonstrated that responses to fluoxetine, even at therapeutic doses, can vary significantly between individuals. Similar dosages can have divergent results due to polymorphism in the genes that code for the isoforms responsible for the metabolism of drugs. Drug treatment response can be influenced by several factors, such as age, organ function, environmental factors and the nature and severity of disease, however, genetic polymorphisms account for most variations in treatment responses. The early diagnosis of genetically predisposed deficiency, based on molecular genetic methods, will lead to early recognition of serotonin toxicity and early intervention.

**Acknowledgements**

None.

**Conflict of interest**

Author declares that there is no conflict of interest.

**References**

1. Iqb Sl MM, Basil MJ, Kaplan J, et al. Overview of serotonin syndrome. \textit{Ann Clin Psychiatry}. 2012;24(4):310–318.
2. Lambirg JI, Gordin VN. Serotonin syndrome in a patient with chronic pain polypharmacy. \textit{Pain Med}. 2012;13(8):1429–1431.
3. Murphy DL, Lerner A, Rudnick G, et al. Serotonin transporter: gene, genetic disorders, and pharmacogenetics. \textit{Mol Interv}. 2004;4(2):109–123.
4. Perry PJ, Wilborn CA. Serotonin syndrome vs neuroleptic malignant syndrome: a contrast of causes, diagnoses, and management. \textit{Ann Clin Psychiatry}. 2012;24(2):155–162.
5. Watts SW, Morrison SF, Davis RP, et al. Serotonin and blood pressure regulation. \textit{Pharmacol Rev}. 2012;64(2):359–388.
6. Wilson L, Rooney T, Baugh RF, et al. Recognition and management of perioperative serotonin syndrome. \textit{Ann J Otolaryngol}. 2012;33(3):319–321.
7. Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. \textit{BMJ}. 2014;348:g1626.
8. Isbister GK, Buckley NA, Whyte IM. Serotonin toxicity: a practical approach to diagnosis and treatment. \textit{Med J Aust}. 2007;187(6):361–365.
9. Pan JJ, Shen WW. Serotonin syndrome induced by low-dose venlafaxine. \textit{Ann Pharmacother}. 2003;37(2):209–211.
10. Guo SL, Wu TJ, Liu CC, et al. Meperidine-induced serotonin syndrome in a susceptible patient. \textit{Br J Anaesth}. 2009;103(3):369–370.
11. Phan H, Casavant MJ, Crockett S, et al. Serotonin syndrome following a single 50 mg dose of sertraline in a child. \textit{Clin Toxicol (Phila)}. 2008;46(9):845–840.
12. Mullins ME, Horowitz BZ. Serotonin syndrome after a single dose of fluvoxamine. \textit{Ann Emerg Med}. 1999;34(6):806–807.

**Citation:** Piatkov I, Mann G, Jones T, et al. Serotonin toxicity and cytochrome p450 poor metaboliser genotype patient case. \textit{J Investig Genomics}. 2017;4(1):1–5.

**DOI:** 10.15406/jig.2017.04.00054
Serotonin toxicity and cytochrome p450 poor metaboliser genotype patient case.

13. Gill M, LoVecchio F, Selden B. Serotonin syndrome in a child after a single dose of fluoxetine. Ann Emerg Med. 1999;33(4):457–459.

14. Laje G, McMahon FJ. Genome-wide association studies of antidepressant outcome: a brief review. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35(7):1553–1557.

15. Pilgrim JL, Gerostamoulos D, Drummer OH. Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects. Forensic Sci Med Pathol. 2011;7(2):162–184.

16. Sim SC, Ingelman Sundberg M. The human cytochrome P450 (CYP) allele nomenclature website: a peer-reviewed database of CYP variants and their associated effects. Hum Genomics. 2010;4(4):278–281.

17. Lenz T, Malhotra AK. Pharmacogenomics of antidepressant-induced side effects. Dialogues Clin Neurosci. 2009;11(4):405–415.

18. Zahari Z, Salleh MR, Teh LK, et al. Influence of CYP2D6 polymorphisms on symptomatology and side-effects of patients with schizophrenia in Malaysia. Malays J Med Sci. 2009;16(3):12–20.

19. Lucire Y, Crotty C. Antidepressant-induced akathisia-related homicides associated with diminishing mutations in metabolizing genes of the CYP450 family. Pharmacog Rev. 2011;5:65–81.

20. Fox MA, Panessiti MG, Moya PR, et al. Mutations in monoamine oxidase (MAO) genes in mice lead to hypersensitivity to serotonin-enhancing drugs: implications for drug side effects in humans. Pharmacogenomics J. 2013;13(6):551–557.

21. Davies MA, Conley Y, Roth BL. Functional SNPs in genes encoding the 5-HT2A receptor modify the affinity and potency of several atypical antipsychotic drugs. Biol Res Nurs. 2011;13(1):55–60.

22. Iwahashi K, Murayama O, Aoki J, et al. [Influence of serotonin (5-HT) 2A-receptor and transporter (5HTT) gene polymorphism upon the effect of olanzapine]. Nihon Shinkin Seishin Yakurigaku Zasshi. 2009;29(4):141–144.

23. Piartkov I, Jones T, Rochester C. Cytochrome P450 loss-of-function polymorphism genotyping on the Agilent Bioanalyzer and clinical application. Pharmacogenomics. 2010;11(12):1987–1994.

24. Hoffmann MF, Preisser SC, Nickel J, et al. The transformer database: biotransformation of xenobiotics. Nucleic Acids Res. 2014;42(Database issue):D1113–D1117.

25. Hicks JK, Swen JJ, Thorn CF, et al. Clinical pharmacogenetics implementation consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther. 2013;93(5):402–408.

26. Hodgson K, Tansey K, Dernovsek MZ, et al. Genetic differences in cytochrome P450 enzymes and antidepressant treatment response. J Psychopharmacol. 2014;28(2):133–141.

27. Soderberg MM, Haslemo T, Molden E, et al. Influence of CYP1A1/ CYP1A2 and AHR polymorphisms on systemic olanzapine exposure. Pharmacogenet Genomics. 2013;23(5):279–285.

28. Wang Z, Wang S, Huang M, et al. Characterizing the effect of cytochrome P450 (CYP) 2C8, CYP2C9, and CYP2D6 genetic polymorphisms on stereoselective N-demethylation of fluoxetine. Chirality. 2014;26(3):166–173.

29. Kagimoto M, Heim M, Kagimoto K, et al. Multiple mutations of the human cytochrome P450ID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem. 1990;265(28):17209–17214.

30. Butwicka A, Krystyna S, Retka W, et al. Neuroleptic malignant syndrome in an adolescent with CYP2D6 deficiency. Eur J Pediatr. 2014;173(12):1639–1642.

31. Batty JA, Hall AS, White HL, et al. An investigation of CYP2D6 genotype and response to metoprolol CR/XL during dose titration in patients with heart failure: a MERIT-HF sub study. Clin Pharmacol Ther. 2014;95(3):321–330.

32. Parkman HP, Mishra A, Jacobs M, et al. Clinical response and side effects of metoclopramide: associations with clinical, demographic, and pharmacogenetic parameters. J Clin Gastroenterol. 2012;46(6):494–503.

33. Sirachainan E, Jarathurai S, Trachu N, et al. CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients. Pharmacogenomics Pers Med. 2012;5:149–153.

34. van der Merwe N, Bouwens CS, Pienaar R, et al. CYP2D6 genotyping and use of antidepressants in breast cancer patients: test development for clinical application. Metab Brain Dis. 2012;27(3):319–326.

35. Yalcintepe S, Ozdemir O, Silan C, et al. The CYP4502D6 *4 and *6 alleles are the molecular genetic markers for drug response: implications in cloxicaine non-responder FMF patients. Eur J Drug Metab Pharmacokinet. 2015;41(3):281–286.

36. Caccamo D, Cesareo E, Mariani S, et al. Xenobiotic sensor- and metabolism-related gene variants in environmental sensitivity-related illnesses: a survey on the Italian population. Oxid Med Cell Longev. 2013;2013:831969.

37. Shukla P, Gupta D, Pant MC, et al. CYP 2D6 polymorphism: a predictor of susceptibility and response to chemoradiotherapy in head and neck cancer. J Cancer Res Ther. 2012;8(1):40–45.

38. Baranska M, Dziakowska Bartkowiak B, Waszczykowska E, et al. Significance of genetic polymorphism of CYP2D6 in the pathogenesis of systemic sclerosis. Pharmacol Rep. 2012;64(2):336–342.

39. Lu Y, Mo C, Zeng Z, et al. CYP2D6*4 allele polymorphism increases the risk of Parkinson’s disease: evidence from meta-analysis. PLoS one. 2013;8(12):e84413.

40. Bijl MJ, Visser LE, Hofman A, et al. Influence of the CYP2D6*4 polymorphism on dose, switching and discontinuation of antidepressants. Br J Clin Pharmacol. 2008;65(4):558–564.

41. Shimoda K, Someya T, Yokono A, et al. The impact of CYP2C19 and CYP2C9 genotypes on metabolism of amitriptyline in Japanese psychiatric patients. J Clin Psychopharmacol. 2002;22(4):371–378.

42. Suzuki Y, Sugai T, Fukui N, et al. CYP2D6 genotype and smoking influence fluvoxamine steady-state concentration in Japanese psychiatric patients: lessons for genotype-phenotype association study design in translational pharmacogenetics. J Psychopharmacol. 2011;25(7):908–914.

43. Nakamura K, Aiyoshi N, Yokoi T, et al. CYP2D6*10 present in human liver microsomes shows low catalytic activity and thermal stability. Biochem Biophys Res Commun. 2002;293(3):969–973.

44. Kubota T, Chiba K, Ishizaki T. Genotyping of S-mephenytoin 4'-hydroxylation in an extended Japanese population. Clin Pharmacol Ther. 1996;60(6):661–666.

45. Inomata S, Kang JM, Kim N, Lee DH, et al. Effect of the CYP2C19 polymorphism on emtricitabine and tenofovir pharmacokinetics and emergence of resistance. J Investig Genomics. 2017;4(1):1–5.

Citation: Piatkov I, Mann G, Jones T, et al. Serotonin toxicity and cytochrome p450 poor metaboliser genotype patient case. J Investig Genomics. 2017;4(1):1–5. DOI: 10.15406/jig.2017.04.00054
49. Uslu A, Ogus C, Ozdemir T, et al. The effect of CYP1A2 gene polymorphisms on Theophylline metabolism and chronic obstructive pulmonary disease in Turkish patients. *BMB Rep.*, 2010;43(8):530–534.

50. MIMs Online C.

51. Preskorn SH, Shah R, Neff M, et al. The potential for clinically significant drug-drug interactions involving the CYP 2D6 system: effects with fluoxetine and paroxetine versus sertraline. *J Psychiatr Pract.*, 2007;13(1):5–12.

52. von Moltke LL, Greenblatt DJ, Duan SX, et al. Human cytochromes mediating N-demethylation of fluoxetine *in vitro*. *Psychopharmacology* (Berl). 1997;132(4):402–407.

53. Schmider J, Greenblatt DJ, von Moltke LL, et al. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors *in vitro*: studies of phenytoin p-hydroxylation. *Br J Clin Pharmacol.* 1997;44(5):495–498.

54. Kobayashi K, Yamamoto T, Chiba K, et al. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylation activity in human liver microsomes. *Br J Clin Pharmacol.* 1995;40(5):481–485.

55. Hiemke C, Hartter S. Pharmacokinetics of selective serotonin reuptake inhibitors. *Pharmacol Ther.*, 2000;85(1):11–28.

56. FDA. US Food and Drug Administration.

57. Singh MS, Francis PA, Michael M. Tamoxifen, cytochrome P450 genes and breast cancer clinical outcomes. *Breast.*, 2011;20(2):111–118.

58. Spina E, Santoro V, D’Arrigo C. Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update. *Clin Pharmacokinet.* 2008;47(7):637–653.

59. Fjordside L, Jeppesen U, Eap CB, et al. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. *Pharmacogenetics*. 1999;9(1):55–60.

60. Hemeryck A, Belpaire FM. Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update. *Curr Drug Metab.* 2002;3(1):13–37.

61. Sproule BA, Naranjo CA, Brenner KE, et al. Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence. *Clin Pharmacokinet.* 1997;33(6):454–471.

62. Gram L. Fluoxetine. *N Engl J Med.*, 1994;331(20):1354–1361.

63. Fuller RW, Snoddy HD, Krushinski JH, et al. Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors *in vivo*. *Neuropharmacology*. 1992;31(10):997–1000.

64. Benfield P, Heel RC, Lewis SP. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. *Drugs*. 1986;32(6):481–508.

65. Ring BJ, Eckstein JA, Gillespie JS, et al. Identification of the human cytochromes p450 responsible for *in vitro* formation of R- and S-norfloxetine. *J Pharmacol Exp Ther.* 2001;297(3):1044–1050.

66. Margolis JM, O’Donnell JP, Mankowski DC, et al. (R)-, (S)-, and racemic fluoxetine N-demethylation by human cytochrome P450 enzymes. *Drug Metab Dispos.* 2000;28(10):1187–1191.

67. Fjordside L, Jeppesen U, Eap CB, et al. The stereoselective metabolism of fluoxetine in poor and extensive metabolizers of sparteine. *Pharmacogenetics*. 1999;9(1):55–60.

68. Whirl Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. *Clin Pharmacol Ther.* 2012;92(4):414–417.